Maxim Group analyst Jason McCarthy maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) on February 2 and set a price target of $8.00. The company’s shares closed last Friday at $2.76, close to its 52-week low of $2.36.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.
Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $16.67.
The company has a one-year high of $17.01 and a one-year low of $2.36. Currently, Monopar Therapeutics Inc has an average volume of 21.25K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Read More on MNPR:
- Maxim Group Reaffirms Their Buy Rating on Cyclo Therapeutics (CYTH)
- Maxim Group Thinks Inmune Bio’s Stock is Going to Recover
- Maxim Group Thinks Diamedica Therapeutics’ Stock is Going to Recover
- Maxim Group Thinks Clene’s Stock is Going to Recover
- Maxim Group Thinks Entera Bio’s Stock is Going to Recover